No frank biochemical evidence of proteinopathy in the cerebellar cortex of patients with essential tremor
Objective: This study was designed to determine the presence of common types of proteinopathies in the cerebellar cortex of patients who died with essential tremor…Sensitive biomarker of Parkinson’s disease linked to mutations in the glucocerebrosidase gene
Objective: To find a biomarker for development of Parkinson’s disease (PD) in carriers of mutations in the glucocerebrosidase gene (GBA). Background: Mutations in the GBA…Diffusion Magnetic Resonance Imaging with Neurite Orientation and Dispersion Imaging (NODDI) Detects Early Localized Cortex Disruption in Parkinson’s Disease
Objective: To use diffusion kurtosis MRI with NODDI to assess brain cortex microstructure in Parkinson’s patients and localize disease related changes. Background: Cortical atrophy has…Motor, non-motor and cognitive correlates of carotid intima-media thickness in patients with Parkinson’s disease
Objective: To determine the correlation of carotid intima-media thickness (IMT) to motor, non-motor and cognitive scales in patients with Parkinson’s disease (PD). Background: Increased IMT…Difference in distribution between alpha-synuclein oligomers and Lewy bodies in Parkinson’s disease brain
Objective: To examine the distribution of alpha-synuclein (αSYN) oligomers in Parkinson’s disease (PD) brains and compare the distribution of αSYN oligomers and Lewy bodies. Background:…Ampreloxetine (TD-9855), a long-acting, norepinephrine reuptake inhibitor (NRI) for the treatment of neurogenic orthostatic hypotension (nOH) in subjects with synucleinopathies: Phase 3 clinical program
Objective: To confirm: 1) clinical efficacy and safety of once-daily oral ampreloxetine in a 4-week double-blind (DB), placebo-controlled (PC) study (NCT03750552); 2) durability of efficacy…Identification and characterization of anti-prionic compounds that disassemble αSyn prions as a novel therapeutic approach for synucleinopathies
Objective: Stabilization of monomeric α-synuclein protein (αSyn) by transient and high-affinity binding ligands is a novel and highly innovative anti-prionic treatment strategy for synucleinopathies .…Towards a scoring system to distinguish early parkinsonian variant of multiple system atrophy from Parkinson’s disease
Objective: To develop a clinical score to distinguish between the parkinsonian variant of multiple system atrophy (MSA-P) and Parkinson’s disease (PD). Background: The differential diagnosis…Disease stage and UMSARS progression: Implications for clinical trials
Objective: To study the rate of progression of multiple system atrophy (MSA) and assess for a potential ceiling effect of the Unified Multiple System Atrophy…Alpha-synuclein interacts with BAF complex in nucleus
Objective: This study aims to uncover the prospective partner of αS in nucleus. Background: In neuronal cells, large part of alpha-synuclein (αS) localize at presynaptic…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 15
- Next Page »